PMVP - Pmv Pharmaceuticals Inc

PMVP - Pmv Pharmaceuticals Inc

https://www.pmvpharma.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

PMV Pharmaceuticals ( PMVP ) Q2 Loss Jumps

Motley Fool • 1 month, 1 week ago • score: 0.07

PMV Pharmaceuticals ( NASDAQ:PMVP ) , a biotechnology company focused on precision oncology, reported its second quarter 2025 earnings on August 7, 2025. The most notable update was the continued operational investment in its lead asset, rezatapopt, now in a pivotal Phase 2 clinical trial.

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire • 3 months, 3 weeks ago

PRINCETON, N.J., May 23, 2025 ( GLOBE NEWSWIRE ) -- PMV Pharmaceuticals, Inc. ( "PMV Pharma". Nasdaq: PMVP ) , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H.

Here's Why PMV Pharmaceuticals ( PMVP ) Looks Ripe for Bottom Fishing

Zacks Commentary • 6 months, 1 week ago • score: 0.41

PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire • 7 months ago

PRINCETON, N.J., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- PMV Pharmaceuticals, Inc. ( Nasdaq: PMVP ) , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53 mutations in cancer. The company is headquartered in Cranbury, New Jersey.

52W High

$1.82

52W Low

$0.81

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.52

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.24

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.55

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

2.90%

Institutions (25–75% balanced)

66.85%

Shares Outstanding

52,991,000

Float

36,204,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.56

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.46%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0379

Previous

-0.0208

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025